Relevant research found that it can not only target HER2-positive tumor cells but also can effectively target tumor cells that express low levels of HER2 through the bystander effect to neighboring tumor cells heterogeneously expressing HER2 (33–35). Here, ERBB2 is linked to neoplasm.